32 326030.KS SK Biopharmaceuticals Co., Ltd. Loading... : Bullish and Bearish Analyst Opinions

Despite recent underperformance versus US biotech, Korean large-cap biopharma companies (Samsung Biologics, Celltrion, SK Biopharm) have strong R&D pipelines, BD capabilities, and global competitiveness. Q4 will bring major academic conferences and potential tech transfer deals that will re-rate these stocks. Current levels offer an attractive long-term entry point.

Korean large-cap pharma/biotech companies like Celltrion, SK Biopharm, and Samsung Bioepis Holdings have the capital, BD capabilities, and R&D manpower to develop innovative first-in-class drugs. They are expected to produce novel therapies within about 3 years, matching China's rapid growth trajectory. These firms already have global tech-transfer track records and are building the ecosystem despite current stock underperformance.